Arcutis Biotherapeutics files initial beneficial ownership statement for EVP, Chief Commercial Officer Robert Lisicki
ARQT•Robert Lisicki initially disclosed 55,000 Arcutis Biotherapeutics common shares and stock options covering 145,000 shares.
1. Ownership disclosure
Arcutis Biotherapeutics EVP and Chief Commercial Officer Robert Lisicki initially disclosed 55,000 common shares and stock options covering 145,000 shares.
